Tyler Van Buren is a director and senior research analyst at Piper Sandler covering biotechnology companies. Prior to joining Piper Sandler in 2018, Van Buren spent five years at Cowen and Company, where he covered large and smid-cap biopharma companies. In 2017, Institutional Investor recognized Van Buren as the No. 1 Rising Star in the specialty pharma category and the No. 2 Rising Star across therapeutics. Previously, Van Buren was a founding member and managing director at New York-based LifeSci Advisors where he helped build the firm’s biotechnology research practice. Earlier in his career, he worked at Amylin Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham Medical Research Institute and the U.S. Department of Agriculture. Van Buren earned a master’s degree in biology and a bachelor’s degree in biochemistry and cellular biology from the University of California, San Diego.